Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic

被引：0

作者：

Liegeon, Geoffroy ^{[1
]}

Kaperak, Christopher ^{[1
]}

Friedman, Eleanor E. ^{[1
]}

Djuricich, Paul ^{[2
]}

Dawdani, Alicia ^{[1
]}

Stafford, Kane ^{[2
]}

Plotkin, Sophie ^{[1
]}

Schmitt, Jessica ^{[1
]}

Hazra, Aniruddha ^{[1
]}

Christopoulos, Katerina A. ^{[3
]}

Schneider, John A. ^{[1
]}

Mcnulty, Moira C. ^{[1
]}

机构：

[1] Univ Chicago, Dept Med, Chicago, IL USA

[2] Univ Chicago, Dept Pharm, Chicago, IL USA

[3] Univ Calif San Francisco, Div HIV ID & Global Med, San Francisco, CA USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2025年 / 12卷 / 03期

基金：

美国国家卫生研究院;

关键词：

cabotegravir; injectable; long-acting; people with HIV; rilpivirine; PROGRAM; CARE;

D O I：

10.1093/ofid/ofaf094

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We describe referrals and uptake of long-acting injectable cabotegravir/rilpivirine at an academic clinic in Chicago. In a pharmacy-led model, 118 (18%) people with HIV were referred and 78 (12%) initiated long-acting injectable cabotegravir/rilpivirine from 1 January 2021 to 31 May 2023. Implementation, especially for people with HIV who were not virally suppressed, requires further support for patients, providers, and clinic systems.

引用

页数：7

共 50 条

[21] An evaluation of long-acting cabotegravir plus rilpivirine for the treatment of virologically suppressed adults living with HIV
Qazzaz, Hamdi
Parganas, Christopher
Cory, Theodore James
EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (13) : 1485 - 1495
[22] Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk
Masia, Mar
Fernandez-Gonzalez, Marta
Ledesma, Christian
Losada-Echeberria, Maria
Gonzalo-Jimenez, Nieves
Mascarell, Paula
Garcia-Abellan, Javier
Lopez, Leandro
Bello-Perez, Melissa
Padilla, Sergio
Gutierrez, Felix
JOURNAL OF INFECTIOUS DISEASES, 2025,
[23] Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials
Patel, Parul
Ford, Susan L.
Baker, Mark
Meyer, Claudia
Garside, Louise
D'Amico, Ronald
Van Solingen-Ristea, Rodica
Crauwels, Herta
Polli, Joseph W.
Seal, Ciara
Yaguee Munoz, Itziar
Thiagarajah, Shanker
Birmingham, Eileen
Spreen, William R.
Baugh, Bryan
van Wyk, Jean
Vannappagari, Vani
HIV MEDICINE, 2023, 24 (05) : 568 - 579
[24] Process evaluation and early outcomes of real-world implementation of a pharmacist-driven cabotegravir/rilpivirine long-acting injectable initiative
Derrick, Caroline B.
Magee, Matthew
Tsai, Y. Vivian
Pizzuti, Morgan E.
Parker, Sarah
Lucas, Omar
Taylor, Kara
Albright, Raeghan
Langehans, Briley
Schreiber, Danny
Guest, Georgia
Ahuja, Divya
Weissman, Sharon
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2024,
[25] Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience
Castelli, Alessandro
Lanzafame, Massimiliano
Morra, Matteo
Bertoldi, Marco
Delama, Andrea
Fait, Daniela
Vento, Sandro
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2024, 40 (05) : 283 - 285
[26] Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide
Tan, Darrell H. S.
Antinori, Andrea
Eu, Beng
Galindo Puerto, Maria Jose
Kinder, Clifford
Sweet, Donna
Van Dam, Cornelius N.
Sutton, Kenneth
Sutherland-Phillips, Denise
Berni, Alessandro
Zhang, Feifan
Urbaityte, Rimgaile
Baugh, Bryan
Spreen, William
van Wyk, Jean
Garges, Harmony P.
Patel, Parul
Batterham, Rachel
D'Amico, Ronald
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2025, 98 (04) : 401 - 409
[27] Injectable Long-Acting Cabotegravir-Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start
Pinto, Rogerio M.
Hall, Evan
Tomlin, Ryan
JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE, 2023, 34 (02): : 216 - 220
[28] Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis
Prather, Caitlin
Jeon, Chaeok
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (21) : 1898 - 1905
[29] Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine
Pintado, Claire
Delaugerre, Constance
Molina, Jean-Michel
OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (09):
[30] Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
Moreno, Santiago
Rivero, Antonio
Ventayol, Pere
Falco, Vicenc
Torralba, Miguel
Schroeder, Melanie
Neches, Victoria
Vallejo-Aparicio, Laura Amanda
Mackenzie, Isaac
Turner, Matthew
Harrison, Cale
INFECTIOUS DISEASES AND THERAPY, 2023, 12 (08) : 2039 - 2055

← 1 2 3 4 5 →